Managing Partner
Chen Yu
Dr. Yu is the founder and Managing Partner at TCGX. Prior to founding TCGX, Dr. Yu spent sixteen years as a Managing Partner at Vivo Capital, a life sciences focused investor with $4.5 B AUM. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including stints as the COO of Sagent Pharmaceuticals and CBO of China KangHui, both of which went public and were ultimately acquired. Dr. Yu has served on the board of over a dozen private/public companies, including Artios, Upstream Bio, Structure Therapeutics (NASDAQ:GPCR), Arbor Biotechnologies, Tarsus Pharmaceuticals (NASDAQ: TARS), Sagent Pharmaceuticals (NASDAQ: SGNT, acquired by Nichi-I-Ko), China Kanghui (NYSE:KH, acquired by Medtronic), Rempex (acquired by Medicines Company), Kala (NASDAQ:KALA), Nabriva (NASDAQ: NBRV), Surgical Specialties (acquired by GTCR), Sentre Heart (acquired by Atricure), and NKF Pharma (SHA: 603707). While at Vivo, he also led investments in Zai Labs (NASDAQ: ZLAB), RiverVision (acquired by Horizon), CRISPR Therapeutics (NASDAQ:CRSP), Intellia (NASDAQ: NTLA), Durata (acquired by Actavis), Trauson (acquired by Stryker), and Revolution Medicines (NASDAQ:RVMD).
Dr. Yu also serves on the California Leadership Council for the Nature Conservancy and was previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.
Managing Partner
Cariad Chester
Prior to joining TCGX, Cariad was a Managing Director at Aquilo Capital, where he led investments in biotechnology companies developing human therapeutics. Prior to Aquilo Capital, he served as a research scientist in the lab of Dr. Holbrook Kohrt at Stanford University. His research focused on understanding tumor-immune system interactions during cancer onset, progression, and treatment. He has authored or co-authored over 20 peer-reviewed manuscripts and presented research at conferences in Canada, the US, and China. Cariad has also worked in clinical trial management, helping to launch and coordinate phase I, first-in-human trials of investigational immunotherapeutic agents, and formerly operated a consulting practice advising early-stage companies on assay development and pipeline prioritization. Cariad received his B.A. from Swarthmore College, where he double majored in Neuroscience and Comparative Religious Studies.
Partner
Giuliano Marostica
Prior to joining TCGX, Mr. Marostica was an Associate at Great Point Partners, where he focused on public investments in therapeutics companies. Prior to joining Great Point Partners, he was an analyst in the Healthcare Investment Banking group at Citigroup. Mr. Marostica graduated magna cum laude with a BSc in Biomedical Engineering from Brown University.
Analyst
George Feng
Prior to joining TCGX, George graduated summa cum laude from the Jerome Fisher Program in Management and Technology (M&T) at the University of Pennsylvania. He earned a BSc in Economics from Wharton with a concentration in Finance, as well as a BSc in Bioengineering from the School of Engineering and Applied Science with a concentration in Therapeutics & Drug Delivery. During his studies, George completed internships at Novartis and Point72, a Connecticut-based hedge fund. While on campus, he also consulted for early-stage biotech startups within the university ecosystem.
Associate
Haithem Laaribi
Prior to joining TCGX, Haithem was a Senior Associate at Evercore ISI, focusing on SMID Cap biotech coverage. Prior to Evercore, he was a consultant at Eversana Consulting and Deallus. Haithem received a B.Sc. in Pharmacology from McGill University.
Associate
Susan Wang
Prior to joining TCGX, Susan obtained her PhD in Biomedical Sciences from University of California San Diego School of Medicine. Her research combined CRISPR and live imaging techniques to investigate the dynamics of estrogen dependent transcription regulation in breast cancer, and has authored/co-authored several articles in Nature and Cell journals. During her time in academia, Susan interned at Genentech in Portfolio Management and Strategy after which she joined RTW for therapeutics investments. Susan also worked as a consultant for Avego and Enceladus Bio, where she led scientific diligence in early-stage biotech and helped establish a clinical pipeline. Susan received her B.A. from University of California Berkeley, where she double majored in Molecular Cell Biology and Psychology.